Seqens Invests in US R&D Laboratory
French API specialist Seqens is investing what it says is a multi-million-dollar sum in its US research and development laboratory at Devens, Massachusetts. The company said the improvements will increase its R&D capability and productivity in the US and strengthen its global network. Completion of the project is expected in October 2022.
The investment comes just three months after SK Capital acquired the majority of Seqens and merged it with its portfolio company Wavelength Pharmaceuticals to create a larger, highly diversified CDMO. Alongside SK, new investors Bpifrance and Nov Sante’ now flank existing shareholders Mérieux Equity Partners, Ardian and Eximium.
The merger with Wavelength extends Seqens’ global reach by adding production facilities in Israel and India and sales offices in Europe and the US. It also broadens the French company’s API portfolio and its cytotoxic, steroidal and high-potency products with the addition of Wavelength’s complementary expertise in complex pharmaceutical synthesis.
In total, the expanded portfolio now includes 200 active pharmaceutical ingredients (APIs), 500 pharmaceutical intermediates, as well as key specialty ingredients and chemicals.
In addition to the redevelopment of its Devens lab, Seqens said it is investing significantly across the enterprise to support its customers’ growth in both commercial and development products and technology platforms, including custom polymers, lipids, flow chemistry, high potency APIs and biocatalysts.
Author: Dede Williams, Freelance Journalist
